Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab maintenance in muscle-invasive bladder cancer
NCT03697850Phase 2Active, not recruiting
- Sponsor
- Unicancer
- Start
- Dec 2018
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in Muscle Invasive Bladder Cancer (MIBC), sponsored by Unicancer. Primary endpoint: Disease-Free Survival at 2 years. Started Dec 2018; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
Muscle Invasive Bladder Cancer (MIBC)
Beyond the preview
Go deeper on NCT03697850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697850.